Pixium Vision announces its cash position at 31 March 2021 and provides an update on its activities and financial outlook until the end of 2021.
at 31 March 2021 and provides an update on its activities and financial outlook until the end of 2021.
Paris, 16 April 2021 - 6:00 p.m. CEST - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces a cash position of €9.7 million at 31 March 2021 and reports on its key developments.
Statement of cash flows summary
In thousands of €
10,566.0
(818.4)
(3,639.4)
(10.8)
2,831.8
9,747.6
4,830.6
Net cash outflow from operating activities in the first three months of 2021 totalled €3.6 million, compared to €2.5 million one year earlier. The increased cash outflow was primarily due to the launch of the PRIMAvera clinical trial in Europe and the work begun in connection
25 Stocks Moving in Wednesday s Pre-Market Session
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Meme Share Revival Drives Volume Surge in Handful of Ti
dailymaverick.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymaverick.co.za Daily Mail and Mail on Sunday newspapers.
Argus 2s | Benzinga
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Share:
Second Sight Medical Products Inc (NASDAQ: EYES) shares have soared above 723% over the previous two trading sessions with the stock touching an intraday high of $14.83 on Monday. The shares registered a spike of nearly 103% as of Monday’s closing.
What Happened: The California-based developer and marketer of implantable visual prosthetics said on Friday that the United States Food and Drug Administration had approved its Argus 2s Retinal Prosthesis System.
The Argus 2s is used for the treatment of retinitis pigmentosa and is made up of glasses and a video processing unit to be used in combination with the company’s previously implanted Argus II system.